Timothy Robinson, MD, PhD
DownloadHi-Res Photo
Cards
Appointments
Therapeutic Radiology
Primary
Contact Info
About
Titles
Assistant Professor of Therapeutic Radiology
Biography
Dr. Robinson is a physician scientist and radiation oncologist who specializes in the treatment of hematologic and CNS malignancies, with particular expertise in CNS hematologic malignancies and the use of radiation to improve the outcomes of patients with hematologic malignancies undergoing CAR T-cell therapy. Dr. Robinson has pioneered the use of radiation therapy to improve the outcomes of patients undergoing CAR T-cell therapy, having published the first series demonstrating the safety of bridging radiation therapy for patients with DLBCL undergoing CAR T-cell therapy, as well as a seminal patterns of failure study in DLBCL patients treated with CAR T, which showed that over a third of treatment failures in DLBCL treated with CAR T are local-only, suggesting a rationale for aggressive bridging radiation therapy in patients with relatively localized or high risk disease. Dr. Robinson currently leads the palliative inpatient consult service at Smilow Cancer Center.
In addition to his clinical research and practice, Dr. Robinson has a translational research program focused on aberrant mRNA splicing in hematologic malignancies and its role in mediating resistance to immune and cellular therapeutics. His lab conducts both bioinformatic and bench-based investigations focused on identifying, validating, and exploiting aberrant mRNA splicing in cancer.
Appointments
Therapeutic Radiology
Assistant ProfessorPrimary
Other Departments & Organizations
- Center for RNA Science and Medicine
- Janeway Society
- Radiobiology
- Radiobiology and Genome Integrity
- Spine Oncology Program
- Therapeutic Radiology
- Yale Medicine
Education & Training
- MD
- Duke University School of Medicine
- PhD
- Duke University School of Medicine
Research
Overview
Medical Subject Headings (MeSH)
Immunotherapy
ORCID
0000-0003-0021-0668
Research at a Glance
Yale Co-Authors
Frequent collaborators of Timothy Robinson's published research.
Publications Timeline
A big-picture view of Timothy Robinson's research output by year.
Michaela Dinan, PhD
Saif Zaman, MD
65Publications
59Citations
Publications
2024
Phase II Trial of Reduced-Intensity Fludarabine, Melphalan 70 Mg/m2, and Total Body Irradiation Conditioning Results in Favorable Outcomes with Haploidentical Donor Peripheral Blood Stem Cell Transplant
Elmariah H, Kim J, DiMaggio E, Gonzalez R, Kim J, Kim J, Mishra A, Faramand R, Perez L, Lazaryan A, Khimani F, Liu H, Ochoa L, Nieder M, Figura N, Robinson T, Nishihori T, Anasetti C, Pidala J, Bejanyan N. Phase II Trial of Reduced-Intensity Fludarabine, Melphalan 70 Mg/m2, and Total Body Irradiation Conditioning Results in Favorable Outcomes with Haploidentical Donor Peripheral Blood Stem Cell Transplant. Transplantation And Cellular Therapy 2024, 30: s58-s59. DOI: 10.1016/j.jtct.2023.12.093.Peer-Reviewed Original ResearchConceptsDisease-free survivalNon-relapse mortalityPost-transplant cyclophosphamidePhase II trialHaplo-PBSCTHematopoietic cell transplantationRate of relapseCumulative incidenceHCT-CIPrimary endpointCumulative incidence of grade II–IV acute GVHDCumulative incidence of non-relapse mortalityIncidence of grade II-IV acute GVHDGrade II-IV acute GVHDGVHD-free relapse-free survivalIncidence of non-relapse mortalityModerate to severe chronic GVHDHematopoietic cell transplantation comorbidity indexMedian follow-up timeChronic GVHD ratesGraft failure eventsHCT-CI scoreSevere chronic GVHDRelapse-free survivalRisk of relapse
2023
Phase II Trial of Reduced-Intensity Fludarabine, Melphalan, and Total Body Irradiation Conditioning Results in Favorable Outcomes with Haploidentical Donor Peripheral Blood Stem Cell Transplant
Elmariah H, Kim J, Mishra A, Faramand R, Perez L, Lazaryan A, Khimani F, Liu H, Ochoa-Bayona J, Nieder M, Figura N, Robinson T, Nishihori T, Anasetti C, Pidala J, Bejanyan N. Phase II Trial of Reduced-Intensity Fludarabine, Melphalan, and Total Body Irradiation Conditioning Results in Favorable Outcomes with Haploidentical Donor Peripheral Blood Stem Cell Transplant. Blood 2023, 142: 4900. DOI: 10.1182/blood-2023-187473.Peer-Reviewed Original ResearchConceptsDisease-free survivalPost-transplant cyclophosphamideHematopoietic cell transplantNon-relapse mortalityPhase II trialTotal body irradiationAllogeneic hematopoietic cell transplantReduced-intensity conditioningBone marrow graftsPrimary endpointII trialCumulative incidenceGVHD prophylaxisCell transplantHematologic malignanciesCyclophosphamide/total body irradiationGVHD-free relapse-free survivalHematopoietic cell transplant comorbidity indexPeripheral blood stem cell graftsSingle-center phase II trialPeripheral blood stem cell transplantBlood stem cell graftsHigh-risk hematologic malignanciesMonths disease free survivalDay 6Bridging Radiotherapy Prior to Chimeric Antigen Receptor T-Cell Therapy for B-Cell Lymphomas: An ILROG Multi-Institutional Study
Yegya-Raman N, Wright C, Ladbury C, Chew J, Zhang S, Sun S, Burke S, Baron J, Sim A, LaRiviere M, Yang J, Robinson T, Tseng Y, Terezakis S, Braunstein S, Dandapani S, Schuster S, Chong E, Plastaras J, Figura N. Bridging Radiotherapy Prior to Chimeric Antigen Receptor T-Cell Therapy for B-Cell Lymphomas: An ILROG Multi-Institutional Study. International Journal Of Radiation Oncology • Biology • Physics 2023, 117: s50-s51. DOI: 10.1016/j.ijrobp.2023.06.333.Peer-Reviewed Original ResearchConceptsImmune effector cell-associated neurotoxicity syndromeProgression-free survivalCytokine release syndromeB-cell lymphomaChimeric antigen receptor T-cell therapySuperior progression-free survivalLarge B-cell lymphomaCAR-T infusionT-cell therapyMulti-institutional studyOverall survivalCTCAE v5.0T infusionTisa-celCAR TRefractory aggressive B-cell lymphomasStage III/IV diseaseT-cell/histiocyte-rich large B-cell lymphomaFavorable progression-free survivalCentral nervous system involvementDiffuse large B-cell lymphomaAggressive B-cell lymphomasPrimary mediastinal B-cell lymphomaMediastinal B-cell lymphomaNervous system involvementEpstein‑Barr virus‑associated primary central nervous system lymphoma in an immunosuppressed patient with a comorbid autoimmune disorder: A case report
Bricoune O, Kareem S, Wallace G, Iacono D, Macaulay R, Etame A, Pina Y, Robinson T, Mokhtari S. Epstein‑Barr virus‑associated primary central nervous system lymphoma in an immunosuppressed patient with a comorbid autoimmune disorder: A case report. Experimental And Therapeutic Medicine 2023, 26: 410. PMID: 37522053, PMCID: PMC10375448, DOI: 10.3892/etm.2023.12109.Peer-Reviewed Original ResearchCitationsAltmetricConceptsPrimary central nervous system lymphomaEpstein-Barr virusCentral nervous system lymphomaDiffuse large B-cell lymphomaNervous system lymphomaMycophenolate mofetilMemory lossSystem lymphomaPeriventricular lesionsEnhancing lesionsBrain MRIEpstein-Barr virus-associated primary central nervous system lymphomaAcetylcholine receptor antibody-positive myasthenia gravisNon-focal neurological symptomsSubsequent chronic kidney diseaseVaricella zoster virus (VZV) vasculopathyAntibody-positive myasthenia gravisWhole-brain radiation therapyLarge B-cell lymphomaComorbid autoimmune disordersLeft eye visionRepeat brain MRIHigh-dose methotrexateVaricella zoster infectionChronic kidney diseaseFeasibility and Toxicity of Full-Body Volumetric Modulated Arc Therapy Technique for High-Dose Total Body Irradiation
Keit E, Liveringhouse C, Figura N, Weygand J, Sandoval M, Garcia G, Peters J, Nieder M, Faramand R, Khimani F, Kim S, Robinson T, Johnstone P, Penagaricano J, Latifi K. Feasibility and Toxicity of Full-Body Volumetric Modulated Arc Therapy Technique for High-Dose Total Body Irradiation. Technology In Cancer Research & Treatment 2023, 22: 15330338231180779. PMID: 37287260, PMCID: PMC10272663, DOI: 10.1177/15330338231180779.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsHigh-dose total body irradiationTotal body irradiationHelical tomotherapyBody irradiationDosimetric outcomesLower lung dosesMucosal sparing techniquesArc therapy (VMAT) techniqueMucosal sparingHead-first positionMyeloablative conditioningDaily fractionsLung dosesAcute leukemiaPrescription doseHT plansDose goalsFFS plansOAR sparingPatientsLow dosesArc therapyUnique protocolDosesVMAT plans
2022
Radiation therapy prior to CAR T-cell therapy in lymphoma: impact on patient outcomes
Figura N, Sim A, Jain M, Chavez J, Robinson T. Radiation therapy prior to CAR T-cell therapy in lymphoma: impact on patient outcomes. Expert Review Of Hematology 2022, 15: 1023-1030. PMID: 36369950, DOI: 10.1080/17474086.2022.2147919.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsCAR T-cell therapyT-cell therapySalvage radiotherapyPatient outcomesAnti-CD19 chimeric antigen receptor (CAR) T-cell therapyChimeric antigen receptor T-cell therapyLarge B-cell lymphomaCurrent retrospective dataHigh tumor burdenClinical risk factorsAblative radiation dosesHypothesis-driven clinical trialsB-cell lymphomaMost patientsR DLBCLLocal recurrenceTumor burdenClinical evidenceRisk factorsTreatment paradigmClinical trialsTreatment outcomesRadiation therapyElevated riskPatientsMulti-Institutional Review of Bridging Radiotherapy Prior to Chimeric Antigen Receptor T-Cell Therapy for B-Cell Lymphomas
Yegya-Raman N, Wright C, Figura N, Zhang S, Chew J, Burke S, Sim A, LaRiviere M, Baron J, Sinha S, Yang J, Robinson T, Jain M, Maity A, Paydar I, Tseng Y, Braunstein S, Schuster S, Chong E, Plastaras J. Multi-Institutional Review of Bridging Radiotherapy Prior to Chimeric Antigen Receptor T-Cell Therapy for B-Cell Lymphomas. Blood 2022, 140: 10900-10901. DOI: 10.1182/blood-2022-157540.Peer-Reviewed Original ResearchClinical outcomes of non-small cell lung cancer brain metastases treated with stereotactic radiosurgery and immune checkpoint inhibitors, EGFR tyrosine kinase inhibitors, chemotherapy and immune checkpoint inhibitors, or chemotherapy alone.
Dohm A, Tang J, Mills M, Liveringhouse C, Sandoval M, Perez B, Robinson T, Creelan B, Gray J, Etame A, Vogelbaum M, Forsyth P, Yu H, Oliver D, Ahmed K. Clinical outcomes of non-small cell lung cancer brain metastases treated with stereotactic radiosurgery and immune checkpoint inhibitors, EGFR tyrosine kinase inhibitors, chemotherapy and immune checkpoint inhibitors, or chemotherapy alone. Journal Of Neurosurgery 2022, 138: 1600-1607. PMID: 36681988, DOI: 10.3171/2022.9.jns221896.Peer-Reviewed Original ResearchCitationsAltmetricConceptsEpidermal growth factor receptor tyrosine kinase inhibitorsImmune checkpoint inhibitorsDistant intracranial controlNon-small cell lung cancer brain metastasesCell lung cancer brain metastasesLung cancer brain metastasesCancer brain metastasesSystemic therapyBrain metastasesStereotactic radiosurgeryCheckpoint inhibitorsLocal controlGrowth factor receptor tyrosine kinase inhibitorsSingle-fraction stereotactic radiosurgeryReceptor tyrosine kinase inhibitorsEGFR tyrosine kinase inhibitorsKinase inhibitorsChemotherapy-alone groupNSCLC BM patientsNSCLC brain metastasesTyrosine kinase inhibitorsBM diagnosisIntracranial controlBM patientsOverall survivalPatient-Level Disease Burden as a Predictor of In-Field Failures in Patients Undergoing Bridging Radiotherapy for CD19-Directed Chimeric Antigen Receptor (CAR) T-Cell Therapy for Recurrent/Refractory Large B-Cell Lymphomas
Figura N, Sim A, Chavez J, Shah B, Khimani F, Lazaryan A, Davila M, Bachmeier C, Nishihori T, Liu H, Christopherson K, Kim S, Locke F, Jain M, Robinson T. Patient-Level Disease Burden as a Predictor of In-Field Failures in Patients Undergoing Bridging Radiotherapy for CD19-Directed Chimeric Antigen Receptor (CAR) T-Cell Therapy for Recurrent/Refractory Large B-Cell Lymphomas. International Journal Of Radiation Oncology • Biology • Physics 2022, 114: s85. DOI: 10.1016/j.ijrobp.2022.07.491.Peer-Reviewed Original ResearchCitationsConceptsMedian metabolic tumor volumeT-cell therapyRefractory large B-cell lymphomaCAR T-cell therapyLarge B-cell lymphomaBRT patientsDisease burdenTotal disease burdenB-cell lymphomaField progressionRadiation therapyLocal controlClinical outcomesExact testChimeric antigen receptor T-cell therapyCAR T-cell infusionDistant-only failureDurable local controlLocal-only failureWorse disease burdenFuture prospective trialsT-cell infusionHigh-risk patientsKaplan-Meier methodLow disease burdenOral Mucosal Sparing in High-Dose Total Body Irradiation (TBI) prior to Stem Cell Transplantation (SCT) for Acute Leukemia
Liveringhouse C, Sandoval M, Dohm A, Weygand J, Garcia G, Peters J, Nieder M, Faramand R, Jain M, Locke F, Bejanyan N, Kim S, Robinson T, Latifi K. Oral Mucosal Sparing in High-Dose Total Body Irradiation (TBI) prior to Stem Cell Transplantation (SCT) for Acute Leukemia. International Journal Of Radiation Oncology • Biology • Physics 2022, 114: e353. DOI: 10.1016/j.ijrobp.2022.07.1462.Peer-Reviewed Original ResearchConceptsNon-relapse mortalityTotal body irradiationStem cell transplantationHigh-grade oral mucositisPlanning target volumeOral mucositisAcute oral mucositisAcute lymphocytic leukemiaAcute leukemiaMucosal sparingOral mucosaExact testRisk of NRMHigh-dose total body irradiationDose total body irradiationHost disease (GVHD) prophylaxisResults 25 patientsMedian patient ageSevere oral mucositisFatal respiratory failureFisher's exact testNon-significant trendIMRT/VMATConditioning chemotherapyFatal GVHD
Clinical Care
Overview
Clinical Specialties
Therapeutic Radiology
Fact Sheets
Lymphoma
Learn More on Yale MedicineHead and Neck Cancer
Learn More on Yale MedicineRadiation Therapy
Learn More on Yale MedicineGerm Cell Tumors
Learn More on Yale Medicine
Board Certifications
Radiation Oncology
- Certification Organization
- AB of Radiology
- Original Certification Date
- 2017
Yale Medicine News
Are You a Patient?
View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.
View Doctor ProfileLinks & Media
News
- March 11, 2024
A Complex Approach to a Rare Cancer
- February 28, 2024
Grants Awarded at YCC • 2024
- September 29, 2023
New Yale Cancer Center Research Highlighted at Top Radiation Oncology Conference
- July 19, 2023
Dr. Timothy Robinson on Yale Cancer Answers
Get In Touch
Contacts
Appointment Number
Locations
Patient Care Locations
Are You a Patient? View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.